(Q38285543)

1 September 2017

1 reference

title

Overcoming the toxicity hurdles of genetically targeted T cells (English)

1 reference

1 September 2017

Monica Casucci

1

1 reference

1 September 2017

Robert E Hawkins

series ordinal

2

1 reference

1 September 2017

Gianpietro Dotti

series ordinal

3

1 reference

1 September 2017

Attilio Bondanza

series ordinal

4

1 reference

1 September 2017

9 December 2014

1 reference

Cancer Immunology, Immunotherapy

1 September 2017

1 reference

1 September 2017

64

1 reference

1 September 2017

1

1 reference

1 September 2017

123-130

1 reference

https://scigraph.springernature.com/pub.10.1007/s00262-014-1641-9

1 September 2017

0 references

cites work

Design and development of therapies using chimeric antigen receptor-expressing T cells

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1641-9

Design and implementation of adoptive therapy with chimeric antigen receptor-modified T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1641-9

Antibody-modified T cells: CARs take the front seat for hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1641-9

Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1641-9

T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1641-9

CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1641-9

Chimeric antigen receptor-modified T cells for acute lymphoid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1641-9

Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1641-9

Cancer regression in patients after transfer of genetically engineered lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1641-9

Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1641-9

T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1641-9

Identification of a Titin-derived HLA-A1-presented peptide as a cross-reactive target for engineered MAGE A3-directed T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1641-9

Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1641-9

Lethal graft-versus-host disease in mouse models of T cell receptor gene therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1641-9

Codon modification of T cell receptors allows enhanced functional expression in transgenic human T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1641-9

Enhanced antitumor activity of murine-human hybrid T-cell receptor (TCR) in human lymphocytes is associated with improved pairing and TCR/CD3 stability

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1641-9

Facilitating matched pairing and expression of TCR chains introduced into human T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1641-9

Improved expression and reactivity of transduced tumor-specific TCRs in human lymphocytes by specific silencing of endogenous TCR.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1641-9

Editing T cell specificity towards leukemia by zinc finger nucleases and lentiviral gene transfer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1641-9

Adoptive immunotherapy with genetically engineered T cells: modification of the IgG1 Fc 'spacer' domain in the extracellular moiety of chimeric antigen receptors avoids 'off-target' activation and unintended initiation of an innate immune response

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1641-9

CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1641-9

Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1641-9

Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1641-9

Targeting of acute myeloid leukaemia by cytokine-induced killer cells redirected with a novel CD123-specific chimeric antigen receptor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1641-9

Preclinical targeting of human acute myeloid leukemia and myeloablation using chimeric antigen receptor-modified T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1641-9

CD44v6-targeted T cells mediate potent antitumor effects against acute myeloid leukemia and multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1641-9

Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1641-9

Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1641-9

Toxicity management for patients receiving novel T-cell engaging therapies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1641-9

Considerations for the clinical application of chimeric antigen receptor T cells: observations from a recombinant DNA Advisory Committee Symposium held June 15, 2010

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1641-9

Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1641-9

Analysis of transgene-specific immune responses that limit the in vivo persistence of adoptively transferred HSV-TK-modified donor T cells after allogeneic hematopoietic cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1641-9

The potential immunogenicity of the TK suicide gene does not prevent full clinical benefit associated with the use of TK-transduced donor lymphocytes in HSCT for hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1641-9

Antitransgene rejection responses contribute to attenuated persistence of adoptively transferred CD20/CD19-specific chimeric antigen receptor redirected T cells in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1641-9

A dual role for genetically modified lymphocytes in cancer immunotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1641-9

HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1641-9

Infusion of suicide-gene-engineered donor lymphocytes after family haploidentical haemopoietic stem-cell transplantation for leukaemia (the TK007 trial): a non-randomised phase I-II study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1641-9

Use of TK-cells in haploidentical hematopoietic stem cell transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1641-9

Molecular mechanism for ganciclovir resistance in human T lymphocytes transduced with retroviral vectors carrying the herpes simplex virus thymidine kinase gene.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1641-9

Elimination of the truncated message from the herpes simplex virus thymidine kinase suicide gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1641-9

An inducible caspase 9 safety switch for T-cell therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1641-9

Inducible apoptosis as a safety switch for adoptive cell therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1641-9

Long-term outcome after haploidentical stem cell transplant and infusion of T cells expressing the inducible caspase 9 safety transgene

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1641-9

Engineering CD19-specific T lymphocytes with interleukin-15 and a suicide gene to enhance their anti-lymphoma/leukemia effects and safety

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1641-9

Mesothelin-specific chimeric antigen receptor mRNA-engineered T cells induce anti-tumor activity in solid malignancies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1641-9

Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1641-9

PD-1- and CTLA-4-based inhibitory chimeric antigen receptors (iCARs) divert off-target immunotherapy responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1641-9

10.1007/S00262-014-1641-9

21 January 2018

Identifiers

DOI

1 reference

Dimensions Publication ID

1 September 2017

0 references

1 reference